Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

283

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions
Paroxysmal Atrial Fibrillation
Interventions
DEVICE

RF Ablation with QDOT Micro

Subjects will be ablated using QDOT Micro catheter

Trial Locations (22)

10016

NYU Langone, New York

10029

Mt. Sinai School of Medicine, New York

10065

New York Presbyterian Hospital, New York

10467

Montefiore Medical Center - Albert Einstein, The Bronx

19104

University of Penn Health System, Philadelphia

23298

Virginia Commonwealth University, Richmond

27610

WakeMed Heart & Vascular, Raleigh

27705

Duke University Medical Center, Durham

32204

Ascension St. Vincent's, Jacksonville

32803

Florida Hospital, Orlando

33462

JFK Medical Center, Atlantis

35243

Grandview Medical Center, Birmingham

35294

University of Alabama, Birmingham

40503

Baptist Health, Lexington

43210

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

55407

Abbott Northwestern Hospital Clinic, Minneapolis

76012

Texas Heart Health and Vascular, Arlington

77030

Houston Methodist Hospital, Houston

78758

St. David's - TCAR, Austin

84107

Intermountain Medical Center, Murray

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Biosense Webster, Inc.

INDUSTRY

NCT03775512 - Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation | Biotech Hunter | Biotech Hunter